Charles River Laboratories (CRL) Gain in connection with sale — Quarterly & Annual

Screener

Gain in connection with sale at other companies

Charles River LaboratoriesCRL

$0—

AtkoreATKR

$0-100%

Corebridge FinancialCRBG

$0—

AllstateALL

$0-100%

Lantheus HoldingsLNTH

$199K—

ZoetisZTS

$0+100%

Other financials

Income statement

Revenue$1.0B-2.7%

Gross profit$349.0M-3.5%

Operating income$119.9M+19.7%

Net income-$1.5M-103%

EPS (diluted)-$0.03-103%

Balance sheet

Cash & equivalents$240.6M+30.2%

Total debt$3.0B+8.1%

Total equity$2.8B-15.3%

Total assets$7.5B-0.4%

Cash flow

Operating cash flow$179.7M-12.2%

CapEx$31.1M-11.9%

Free cash flow$148.6M-12.2%

Valuation

Market cap$13.22B+80.4%

Enterprise value$16.03B+60.9%

P/S3.3×+1.5×

Profitability

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-6%—

FCF margin9.3%-5.1pp

Returns & leverage

Return on equity-7.7%—

Debt / equity1.1×+0.2×

Current ratio1.3×0.0×

Where this comes from

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal.

The source filing: Charles River Laboratories’s 10-K, filed February 11, 2020. Open the filing →

Filed: Feb 11, 2020, 5:22 PM EST
Fiscal year: FY2019
Accession: 0001100682-20-000005

FAQ

What does gain in connection with sale mean?: Gain in connection with sale